We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01239979
First Posted: November 15, 2010
Last Update Posted: December 22, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Isfahan University of Medical Sciences
  Purpose
The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.

Condition
Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease

Resource links provided by NLM:


Further study details as provided by Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • Plasma myeloperoxidase levels [ Time Frame: 3 month ]

Secondary Outcome Measures:
  • Clinical risk factors [ Time Frame: 3 month ]

Biospecimen Retention:   Samples Without DNA
Plasma

Enrollment: 150
Study Start Date: January 2009
Study Completion Date: November 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Stable, Unstable , control

Detailed Description:
Elevation of the leukocyte enzyme myeloperoxidase (MPO) in stable coronary artery disease (CAD) patients in contrast to unstable CAD patients is controversial and its relationship with some inflammatory and noninflammatory markers such as oxidized LDL (ox-LDL) and nitric oxide (NO) in the CAD patients has not been evaluated yet. Evaluation of these relationships is the aim of the study.Also the relationships between MPO and some other inflammatory biomarker such as leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine are examined. This study includes 50 stable CAD, 50 unstable CAD patients and 50 controls. Plasma MPO, ox-LDL, leptin, adiponectin, sPLA2 levels are determined using enzyme immunoassay.Homocysteine and 3-nitrotyrosine are measured using HPLC-fluorescence method. Plasma total NO and other risk factors such as lipid profile, hypertension, smoking, diabetes mellitus and familial history of CAD are also determined in the patients. Results are statistically analysed and the association between all markers are assessed.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
All subjects are diagnosed angiographically following chest pain, clinical manifestations or suspected changes on ECG at Isfahan Cardiovascular Research Center in Iran
Criteria

Inclusion Criteria:

  • Stable and unstable patients with angiographically documented coronary artery disease.
  • Control subjects without angiographically documented coronary artery disease.

All subjects Exclusion Criteria:

  • Patients with recent (with in 6 month) myocardial infarction or cardiovascular events,
  • surgery (with in 3 month),
  • cancer and
  • infective or inflammatory diseases were not included in the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239979


Locations
Iran, Islamic Republic of
Isfahan Cardiovascular Research Center
Isfahan, Iran, Islamic Republic of, 81465-1148
Sponsors and Collaborators
Isfahan University of Medical Sciences
Investigators
Study Director: Saedzaaldin Samsamshariat, PhD - Clinical Biochemistry Department, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  More Information

Responsible Party: Gholam Basati, School of pharmacy and pharmaceutical sciences
ClinicalTrials.gov Identifier: NCT01239979     History of Changes
Other Study ID Numbers: 388417
First Submitted: November 12, 2010
First Posted: November 15, 2010
Last Update Posted: December 22, 2010
Last Verified: January 2009

Keywords provided by Isfahan University of Medical Sciences:
coronary artery disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases